Website profile

Stevens Point

Cancellations, Closures & Delays Meet Our Marketing Gurus Green Gold Fan Zone Never Forgotten Honor Flight Grand Theater 2025-26 Season ↪ How to Listen: Apps & Smart Speakers!

  • 4,237articles · 30d
  • 4+ hour agolatest article
  • Aug 15, 2026earliest in window
  • 15%with images
  • 271avg words
articles per day
Categories
  • News 1,390
  • Economy, Business & Finance 1,334
  • Politics 1,052
  • Finance & Business 1,051
  • Sports & Fitness 934
  • Sports 929
  • Sport 852
  • Sensitive Subjects 670

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Stevens Point
wsau.com > 09/11/2026 > us-fda-approves-scholar-rocks-muscle-weakness-drug

US FDA approves Scholar Rock’s muscle weakness drug

2+ day, 15+ hour ago   (80+ words) Sept 11 (Reuters) - ​The ‌U.S. Food and ‌Drug ​Administration ⁠on ⁠Friday approved Scholar ​Rock's ⁠therapy ⁠to ​treat ​a rare genetic ‌condition ⁠that causes muscle ⁠weakness. (Reporting ‌by ⁠Sneha ​S ‌K in ​Bengaluru; ⁠Editing by Tasim ​Zahid)... US FDA approves Scholar…...

Stevens Point
wsau.com > 09/11/2026 > astrazenecas-breast-cancer-drug-fails-late-stage-trial

Astrazeneca’s breast cancer drug fails late-stage trial

2+ day, 15+ hour ago   (77+ words) Sept 11 (Reuters) - ​AstraZeneca ‌said on Friday ‌its ​breast ⁠cancer ⁠drug failed ​to ⁠meet ⁠the main ​goal ​of improving ‌progression-free survival ⁠during a late-stage ⁠trial. (Reporting ‌by ⁠Christy ​Santhosh ‌in ​Bengaluru; ⁠Editing by Tasim ​Zah... Astrazeneca’s breast cancer drug fails late-stage…...

Stevens Point
wsau.com > 09/10/2026 > novo-nordisk-says-wegovy-approved-in-china-for-liver-disease-mash

Novo Nordisk says Wegovy approved in China for liver disease MASH

4+ day, 4+ hour ago   (146+ words) STOCKHOLM, Sept 10 (Reuters) - Denmark's Novo Nordisk said ​on Thursday ‌its blockbuster weight-loss drug Wegovy had been approved in ‌China ​as ⁠the first ⁠GLP-1 RA class of drugs for the treatment of ​metabolic dysfunction-associated steatohepatitis... STOCKHOLM, Sept 10 (Reuters) – Denmark’s…...

Stevens Point
wsau.com > 09/09/2026 > health-rounds-astrazeneca-drug-reduces-lung-disease-flare-ups-in-late-stage-trials

Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials

5+ day, 1+ hour ago   (872+ words) Sept 9 (Reuters) – Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona. A drug being developed by AstraZeneca significantly reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, researchers reported on…...

Stevens Point
wsau.com > 09/08/2026 > dyne-sarepta-shares-tumble-as-novartis-setback-weighs-on-muscle-disease-drug-developers

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

5+ day, 19+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

Stevens Point
wsau.com > 09/08/2026 > novartis-announces-trial-setback-on-del-desiran-drug

Novartis announces trial setback on del-desiran drug

6+ day, 6+ hour ago   (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s ​impact on myotonic dystrophy, a form ‌of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...

Stevens Point
wsau.com > 09/03/2026 > goodrx-offers-health-subscription-for-families-to-launch-as-employee-benefit-in-2027

GoodRx offers health subscription for families, to launch as employee benefit in 2027

1+ week, 3+ day ago   (326+ words) NEW YORK, Sept 3 (Reuters) – GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and over 250 ​medications, and it plans to launch the program as ‌part of employer health benefits in…...

Stevens Point
wsau.com > 09/01/2026 > alumis-eyes-late-stage-lupus-study-despite-trial-miss

Alumis eyes late-stage lupus study despite trial miss

1+ week, 5+ day ago   (295+ words) Sept 1 (Reuters) – Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even ​after the treatment failed to meet the main goal ‌of a mid-stage trial. Its…...

Stevens Point
wsau.com > 09/01/2026 > novo-nordisk-launches-wegovy-weight-loss-pill-in-germany

Novo Nordisk launches Wegovy weight-loss pill in Germany

1+ week, 6+ day ago   (356+ words) COPENHAGEN, Sep 1 (Reuters) – Novo Nordisk has launched its Wegovy pill in Germany, a spokesperson for the Danish drugmaker said on Tuesday, with investors keenly focused on the oral weight-loss treatment in ​light of intensifying competition with U.S. rival Eli…...

Google News
wsau.com > 08/23/2026 > eli-lilly-launches-oral-weight-loss-pill-foundayo-in-uk

Eli Lilly launches oral weight-loss pill Foundayo in UK | WSAU News/Talk 550 AM · 99.9 FM | Wausau, Stevens Point

3+ week, 13+ hour ago   (168+ words) Aug 24 (Reuters) – Eli Lilly said on Monday it has launched its oral pill, Foundayo, in ​the UK for weight ‌management and type 2 diabetes, making it the first country in Europe where the treatment is available. • ‌The ​pill, known chemically ⁠as…...